Anxiety Medication Overview of Sinequan

The antidepressant doxepin (originally marketed by Pfizer under the brand name Sinequan) is a tricyclic antidepressant approved to treat anxiety disorders. As a medication in this class, doxepin (Sinequan) has a number of possible side effects. Not all people who take the medication will experience side effects, and the duration and severity can also vary between individuals.

Common Side Effects

The most common side effects of doxepin include drowsiness, dizziness or lightheadedness, nausea, constipation, difficulty urinating, dry mouth, weight gain, changes in libido or sexual function, changes in blood sugar levels, and excess sweating.

Serious Side Effects

Severe side effects are rare, but if they occur require immediate medical attention. Serious side effects of doxepin use may include allergic reaction, behavior changes, abnormal thoughts, fainting, hallucinations, sore throat or fever, mood changes, difficulty speaking and swallowing, chest pain, seizures, twitching of the face or tongue, a heartbeat that is fast, slow or irregular, unusual bleeding and bruising, jaundice, and suicidal thoughts.

While many people tolerate doxepin well, it is impossible to know beforehand whether you will experience side effects while taking the medication. Any side effects that are serious or bothersome should be reported to your doctor, so your doxepin dosage can be adjusted or the medication can be discontinued if necessary.

Photo: Pexels

More Articles

There are a number of anti-anxiety medications available, and they can be classified into several different categories of drugs. Not all...

Depression and anxiety are currently considered as separate disorders. Some people clearly have one or the other, but many people experience an...

Selective serotonin-norepinephrine reuptake inhibitors, or SNRIs, are a type of antidepressant often prescribed for anxiety disorders. They are a...

The latest research into the therapeutic possibilities of hallucinogenic mushrooms adds more weight to the argument that psilocybin, when taken in...

I subscribe to the Psychotherapy Networker e-newsletter and just read a great article by Nancy Errebo, Psy. D., about using EMDR with a returning...